Home » VIVUS Provides Qnexa Regulatory Update
VIVUS Provides Qnexa Regulatory Update
VIVUS announced that following recent discussions with FDA officials, the company has been asked to remove the Qnexa contraindication for women of childbearing potential contained in the proposed label.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May